Ana
Fernández Montes
Hospital General Universitario de Elche
Elche, EspañaPublicacións en colaboración con investigadores/as de Hospital General Universitario de Elche (25)
2024
-
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787
-
Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry
Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145
-
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry
Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686
-
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU
Revista espanola de enfermedades digestivas, Vol. 116, Núm. 2, pp. 83-113
-
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432
-
Medical oncology workload, workforce census, and needs in Spain: two nationwide studies by the Spanish Society of medical oncology
Clinical and Translational Oncology, Vol. 26, Núm. 1, pp. 98-108
2023
-
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry
Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089
-
Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study
PLoS ONE, Vol. 18, Núm. 5 May
-
Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study
Cancers, Vol. 15, Núm. 18
-
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Therapeutic Advances in Medical Oncology, Vol. 15
-
The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer
Oncologist, Vol. 28, Núm. 10, pp. E902-E909
-
Utility of CYP2D6 copy number variants as prognostic biomarker in localized anal squamous cell carcinoma
Cancer, Vol. 129, Núm. 16, pp. 2581-2592
2022
-
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100
-
Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry
Biomedicines, Vol. 10, Núm. 1
-
SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)
Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 658-669
-
Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
ESMO Open, Vol. 7, Núm. 3
2021
-
Ascertaining breast cancer patient experiences through a journey map: A qualitative study protocol
PLoS ONE, Vol. 15, Núm. 12 December
-
Breast cancer patient experiences through a journey map: A qualitative study
PLoS ONE, Vol. 16, Núm. 9 September
-
Correction to: Optimism and social support as contributing factors to spirituality in Cancer patients (Supportive Care in Cancer, (2021), 29, 6, (3367-3373), 10.1007/s00520-020-05954-4)
Supportive Care in Cancer
-
Multidimensional Scale of Perceived Social Support (MSPSS) in Cancer Patients: Psychometric Properties and Measurement Invariance
Psicothema, Vol. 33, Núm. 1, pp. 131-138